A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma

Francesco Angrilli; Elsa Pennese; Alessandro Di Marzio; Elisabetta Liberatore; Roberto Di Lorenzo; Giuseppe Fioritoni

A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma

Haematologica. 2002 Nov;87(11):1227-9.

Authors

Francesco Angrilli, Elsa Pennese, Alessandro Di Marzio, Elisabetta Liberatore, Roberto Di Lorenzo, Giuseppe Fioritoni

PMID: 12414356

Abstract

We treated 30 consecutive untreated patients aged > 70 years with advanced aggressive non-Hodgkin's lymphoma with 6 courses of cyclophosphamide, mitoxantrone, etoposide, bleomycin, vinblastine and dexamethasone (D-VICEMB). The global response was 93%. The 6-year overall survival and progression-free survival were 50%, and disease-free survival was 63%.

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Bleomycin / administration & dosage
Cyclophosphamide / administration & dosage
Dexamethasone / administration & dosage
Disease-Free Survival
Etoposide / administration & dosage
Female
Follow-Up Studies
Humans
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / mortality
Male
Methotrexate / administration & dosage
Survival Rate
Vinblastine / administration & dosage

Substances

Bleomycin
Vinblastine
Etoposide
Dexamethasone
Cyclophosphamide
Methotrexate